|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:ANXA5-CCNA2 (FusionGDB2 ID:5175) |
Fusion Gene Summary for ANXA5-CCNA2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ANXA5-CCNA2 | Fusion gene ID: 5175 | Hgene | Tgene | Gene symbol | ANXA5 | CCNA2 | Gene ID | 308 | 890 |
| Gene name | annexin A5 | cyclin A2 | |
| Synonyms | ANX5|ENX2|HEL-S-7|PP4|RPRGL3 | CCN1|CCNA | |
| Cytomap | 4q27 | 4q27 | |
| Type of gene | protein-coding | protein-coding | |
| Description | annexin A5CBP-IPAP-IVAC-alphaanchorin CIIannexin Vannexin-5calphobindin Iendonexin IIepididymis secretory protein Li 7lipocortin Vplacental anticoagulant protein 4placental anticoagulant protein Ithromboplastin inhibitorvascular anticoagulan | cyclin-A2cyclin-A | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | P08758 | P20248 | |
| Ensembl transtripts involved in fusion gene | ENST00000296511, ENST00000501272, ENST00000515017, ENST00000509016, | ENST00000274026, | |
| Fusion gene scores | * DoF score | 7 X 8 X 4=224 | 6 X 2 X 2=24 |
| # samples | 8 | 6 | |
| ** MAII score | log2(8/224*10)=-1.48542682717024 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(6/24*10)=1.32192809488736 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: ANXA5 [Title/Abstract] AND CCNA2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | ANXA5(122602825)-CCNA2(122742246), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | CCNA2 | GO:0000086 | G2/M transition of mitotic cell cycle | 1312467 |
| Tgene | CCNA2 | GO:0016572 | histone phosphorylation | 11746698 |
| Tgene | CCNA2 | GO:0044843 | cell cycle G1/S phase transition | 1312467 |
| Fusion gene breakpoints across ANXA5 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across CCNA2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | STAD | TCGA-VQ-A8DZ | ANXA5 | chr4 | 122602825 | - | CCNA2 | chr4 | 122742246 | - |
Top |
Fusion Gene ORF analysis for ANXA5-CCNA2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000296511 | ENST00000274026 | ANXA5 | chr4 | 122602825 | - | CCNA2 | chr4 | 122742246 | - |
| Frame-shift | ENST00000501272 | ENST00000274026 | ANXA5 | chr4 | 122602825 | - | CCNA2 | chr4 | 122742246 | - |
| intron-3CDS | ENST00000515017 | ENST00000274026 | ANXA5 | chr4 | 122602825 | - | CCNA2 | chr4 | 122742246 | - |
| 5UTR-3CDS | ENST00000509016 | ENST00000274026 | ANXA5 | chr4 | 122602825 | - | CCNA2 | chr4 | 122742246 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for ANXA5-CCNA2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for ANXA5-CCNA2 |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ANXA5 | CCNA2 |
| FUNCTION: This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade. | FUNCTION: Cyclin which controls both the G1/S and the G2/M transition phases of the cell cycle. Functions through the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2. The cyclin subunit confers the substrate specificity of these complexes and differentially interacts with and activates CDK1 and CDK2 throughout the cell cycle. {ECO:0000269|PubMed:1312467}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for ANXA5-CCNA2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for ANXA5-CCNA2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ANXA5-CCNA2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | ANXA5 | P08758 | DB09130 | Copper | Small molecule | Approved|Investigational | |
| Hgene | ANXA5 | P08758 | DB09130 | Copper | Small molecule | Approved|Investigational | |
| Hgene | ANXA5 | P08758 | DB09130 | Copper | Small molecule | Approved|Investigational | |
| Hgene | ANXA5 | P08758 | DB09130 | Copper | Small molecule | Approved|Investigational | |
| Hgene | ANXA5 | P08758 | DB00591 | Fluocinolone acetonide | Inducer | Small molecule | Approved|Investigational|Vet_approved |
| Hgene | ANXA5 | P08758 | DB00591 | Fluocinolone acetonide | Inducer | Small molecule | Approved|Investigational|Vet_approved |
| Hgene | ANXA5 | P08758 | DB00591 | Fluocinolone acetonide | Inducer | Small molecule | Approved|Investigational|Vet_approved |
| Hgene | ANXA5 | P08758 | DB00591 | Fluocinolone acetonide | Inducer | Small molecule | Approved|Investigational|Vet_approved |
Top |
Related Diseases for ANXA5-CCNA2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ANXA5 | C0007137 | Squamous cell carcinoma | 1 | CTD_human |
| Hgene | ANXA5 | C0019202 | Hepatolenticular Degeneration | 1 | CTD_human |
| Hgene | ANXA5 | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human |
| Hgene | ANXA5 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Hgene | ANXA5 | C0024623 | Malignant neoplasm of stomach | 1 | CTD_human |
| Hgene | ANXA5 | C0026640 | Mouth Neoplasms | 1 | CTD_human |
| Hgene | ANXA5 | C0026998 | Acute Myeloid Leukemia, M1 | 1 | CTD_human |
| Hgene | ANXA5 | C0032914 | Pre-Eclampsia | 1 | CTD_human |
| Hgene | ANXA5 | C0038356 | Stomach Neoplasms | 1 | CTD_human |
| Hgene | ANXA5 | C0043094 | Weight Gain | 1 | CTD_human |
| Hgene | ANXA5 | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
| Hgene | ANXA5 | C0153381 | Malignant neoplasm of mouth | 1 | CTD_human |
| Hgene | ANXA5 | C1527352 | Hepatic Form of Wilson Disease | 1 | CTD_human |
| Hgene | ANXA5 | C1708349 | Hereditary Diffuse Gastric Cancer | 1 | CTD_human |
| Hgene | ANXA5 | C1879321 | Acute Myeloid Leukemia (AML-M2) | 1 | CTD_human |
| Tgene | CCNA2 | C0020796 | Profound Mental Retardation | 1 | CTD_human |
| Tgene | CCNA2 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Tgene | CCNA2 | C0025363 | Mental Retardation, Psychosocial | 1 | CTD_human |
| Tgene | CCNA2 | C0036341 | Schizophrenia | 1 | PSYGENET |
| Tgene | CCNA2 | C0917816 | Mental deficiency | 1 | CTD_human |
| Tgene | CCNA2 | C1168401 | Squamous cell carcinoma of the head and neck | 1 | CTD_human |
| Tgene | CCNA2 | C3714756 | Intellectual Disability | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies